Denali Therapeutics Inc NASDAQ NMS - GLOBAL MARKET:DNLI
The leadership team, board of directors, and 10% beneficial owners of Denali Therapeutics Inc, reconstructed from SEC insider filings and proxy statements.
Other Reporting Persons
Other Section-16 reporting persons associated with the issuer.
Baker Brothers Life Sciences LP
—3,405,393 sharesFLATLEY JAY T
—336,313 sharesHo Carole
—25,000 sharesKrognes Steve E.
—781,797 sharesSchenkein David P
—31,232 sharesSchuth Alexander O.
—523,749 sharesTessier-Lavigne Marc
—78,848 sharesWatts Ryan J.
—2,152,604 shares
Recent Form 4 Activity last 90 days
No insider transactions in the last 90 days.
View all insider tradesMethodology
Officers and directors are derived from SEC Forms 3, 4, and 5 filed by reporting persons for this issuer. The roster reflects the most recent disclosed relationship per individual. Officer titles use the issuer-supplied designation from the relationship record.
Independence flags and board committee assignments are sourced from the most recent DEF 14A proxy statement when available. For executive compensation context — base salary, equity grants, performance metrics — refer to the Summary Compensation Table in the issuer's annual proxy.
Cross-references: where a reporting person is matched to a consolidated people profile (same CIK across multiple issuers), the person link routes to the unified profile page so you can see every board seat and officer role in one place.